We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A post-marketing study on immunomodulating treatments for relapsing-remitting multiple sclerosis in Lombardia: preliminary results.
- Authors
Milanese, C.; Beghi, E.; Giordano, L.; Mantia, L.; Mascoli, N.; Confalonieri, P.
- Abstract
The preliminary results of a post-marketing study on relapsing-remitting multiple sclerosis patients treated with immunomodulating agents attending the Lombardia Region’s Multiple Sclerosis Centers are presented. A total of 294 patients treated with Betaferon (67), Avonex (115), Rebif 22 (45), Rebif 44 (18) and Copaxone (49) were included. Relapse frequency consistently decreases at 1 year and continues to decrease after 5 years of treatment, without differences between therapeutic groups. Eighty-seven out of 294 patients (29.6%) discontinued treatment for different reasons. Forty-eight of them shifted to a second therapeutic agent. A different trend, to lower or higher doses of interferon or immunosuppression, according to reasons of discontinuation, was observed.
- Subjects
MULTIPLE sclerosis; MEDICAL research; PATIENTS; IMMUNOSUPPRESSION; INTERFERONS; THERAPEUTICS; NEUROSCIENCES
- Publication
Neurological Sciences, 2005, Vol 26, ps171
- ISSN
1590-1874
- Publication type
Article
- DOI
10.1007/s10072-005-0509-3